NewAmsterdam Pharma Plunges 13.81% on Earnings Miss

On April 10, 2025, NewAmsterdam Pharma's stock experienced a significant drop of 13.81% in pre-market trading, indicating a notable shift in investor sentiment towards the company.

NewAmsterdam Pharma has been facing challenges in its stock performance, with both short and long-term moving averages signaling sell indications. This technical analysis suggests a more negative outlook for the stock, which could be contributing to the recent decline.

Additionally, the company reported earnings per share (EPS) of ($0.95) for the quarter, falling short of analysts' consensus estimates of ($0.48) by ($0.47). This earnings miss has likely added to the negative sentiment surrounding the stock, as investors react to the company's financial performance.

Furthermore, NewAmsterdam Pharma's stock has recently hit a new 52-week low, trading as low as $14.06 during mid-day trading on Monday. This price movement underscores the challenges the company is currently facing, as its stock continues to underperform in the market.

Despite these setbacks, it is important to note that NewAmsterdam Pharma is actively engaged in clinical trials, with additional data reported from the Phase 3 trial of Obicetrapib (BROOKLYN). This ongoing research and development could potentially provide a catalyst for future growth and investor confidence in the company.